Year: - Any -2023202220212020201920182017 Items per page 102550 Date Title Jan 27, 2023 Summary ToggleSol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings Jan 27, 2023 Summary ToggleSol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million Nov 10, 2022 Summary ToggleSol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update Oct 03, 2022 Summary ToggleSol-Gel Technologies Appoints Michael Glezin Vice President, Business Development Aug 04, 2022 Summary ToggleSol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update Jun 02, 2022 Summary ToggleGalderma Launches EPSOLAY® Cream, a Medical Advance to Treat Bumps and Blemishes of Rosacea Jun 01, 2022 Summary ToggleSol-Gel Technologies to Participate in the 2022 Jefferies Global Healthcare Conference May 17, 2022 Summary ToggleSol-Gel Technologies to Present in Upcoming H.C. Wainwright Global Investment Conference May 13, 2022 Summary ToggleSol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update Apr 25, 2022 Summary ToggleSol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY® Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last
Year: - Any -2023202220212020201920182017 Items per page 102550 Date Title Jan 27, 2023 Summary ToggleSol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings Jan 27, 2023 Summary ToggleSol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million Nov 10, 2022 Summary ToggleSol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update Oct 03, 2022 Summary ToggleSol-Gel Technologies Appoints Michael Glezin Vice President, Business Development Aug 04, 2022 Summary ToggleSol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update Jun 02, 2022 Summary ToggleGalderma Launches EPSOLAY® Cream, a Medical Advance to Treat Bumps and Blemishes of Rosacea Jun 01, 2022 Summary ToggleSol-Gel Technologies to Participate in the 2022 Jefferies Global Healthcare Conference May 17, 2022 Summary ToggleSol-Gel Technologies to Present in Upcoming H.C. Wainwright Global Investment Conference May 13, 2022 Summary ToggleSol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update Apr 25, 2022 Summary ToggleSol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY® Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last